443 related articles for article (PubMed ID: 19375930)
21. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.
Chadha M; Capala J; Coderre JA; Elowitz EH; Iwai J; Joel DD; Liu HB; Wielopolski L; Chanana AD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):829-34. PubMed ID: 9531367
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT.
Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Asano T; Kirihata M; Ono K; Kuroiwa T
J Neurooncol; 2006 Jul; 78(3):227-32. PubMed ID: 16557351
[TBL] [Abstract][Full Text] [Related]
23.
Watabe T; Ikeda H; Nagamori S; Wiriyasermkul P; Tanaka Y; Naka S; Kanai Y; Hagiwara K; Aoki M; Shimosegawa E; Kanai Y; Hatazawa J
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):321-331. PubMed ID: 27550420
[TBL] [Abstract][Full Text] [Related]
24. Hydroxylforms of p-boronophenylalanine as potential boron carriers on boron neutron capture therapy for malignant brain tumors.
Takagaki M; Ono K; Oda Y; Kikuchi H; Nemoto H; Iwamoto S; Cai J; Yamamoto Y
Cancer Res; 1996 May; 56(9):2017-20. PubMed ID: 8616843
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the total distribution volume of
Romanov V; Isohashi K; Alobthani G; Beshr R; Horitsugi G; Kanai Y; Naka S; Watabe T; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2020 Mar; 34(3):155-162. PubMed ID: 31808134
[TBL] [Abstract][Full Text] [Related]
26. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma.
Imahori Y; Ueda S; Ohmori Y; Kusuki T; Ono K; Fujii R; Ido T
J Nucl Med; 1998 Feb; 39(2):325-33. PubMed ID: 9476945
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [
Watanabe T; Hattori Y; Ohta Y; Ishimura M; Nakagawa Y; Sanada Y; Tanaka H; Fukutani S; Masunaga SI; Hiraoka M; Ono K; Suzuki M; Kirihata M
BMC Cancer; 2016 Nov; 16(1):859. PubMed ID: 27821116
[TBL] [Abstract][Full Text] [Related]
28. In vivo 19F MR imaging and spectroscopy for the BNCT optimization.
Porcari P; Capuani S; D'Amore E; Lecce M; La Bella A; Fasano F; Migneco LM; Campanella R; Maraviglia B; Pastore FS
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S365-8. PubMed ID: 19375924
[TBL] [Abstract][Full Text] [Related]
29. Biokinetic analysis of tissue boron (¹⁰B) concentrations of glioma patients treated with BNCT in Finland.
Koivunoro H; Hippeläinen E; Auterinen I; Kankaanranta L; Kulvik M; Laakso J; Seppälä T; Savolainen S; Joensuu H
Appl Radiat Isot; 2015 Dec; 106():189-94. PubMed ID: 26363564
[TBL] [Abstract][Full Text] [Related]
30. On the applicability of [
Grunewald C; Sauberer M; Filip T; Wanek T; Stanek J; Mairinger S; Rollet S; Kudejova P; Langer O; Schütz C; Blaickner M; Kuntner C
Nucl Med Biol; 2017 Jan; 44():83-89. PubMed ID: 27837726
[TBL] [Abstract][Full Text] [Related]
31. The importance of optimal ROIs delineation for FBPA-PET before BNCT.
Lo YW; Lee JC; Hu YS; Li CY; Chen YL; Lin CS; Huang WS; Lin KH; Chen YW
Appl Radiat Isot; 2020 Sep; 163():109219. PubMed ID: 32561058
[TBL] [Abstract][Full Text] [Related]
32. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study.
Bergenheim AT; Capala J; Roslin M; Henriksson R
J Neurooncol; 2005 Feb; 71(3):287-93. PubMed ID: 15735919
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients.
Kawabata S; Miyatake S; Nonoguchi N; Hiramatsu R; Iida K; Miyata S; Yokoyama K; Doi A; Kuroda Y; Kuroiwa T; Michiue H; Kumada H; Kirihata M; Imahori Y; Maruhashi A; Sakurai Y; Suzuki M; Masunaga S; Ono K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S15-8. PubMed ID: 19398348
[TBL] [Abstract][Full Text] [Related]
34. L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: a new strategy to improve BNCT efficacy.
Capuani S; Gili T; Bozzali M; Russo S; Porcari P; Cametti C; D'Amore E; Colasanti M; Venturini G; Maraviglia B; Lazzarino G; Pastore FS
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):562-7. PubMed ID: 18793958
[TBL] [Abstract][Full Text] [Related]
35. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine.
Yang W; Barth RF; Rotaru JH; Moeschberger ML; Joel DD; Nawrocky MM; Goodman JH
J Neurooncol; 1997 May; 33(1-2):59-70. PubMed ID: 9151224
[TBL] [Abstract][Full Text] [Related]
36. Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine.
Yang W; Barth RF; Bartus RT; Rotaru JH; Moeschberger ML; Ferketich AK; Nawrocky MM; Coderre JA; Goodman JH
Neurosurgery; 2000 Jul; 47(1):189-97; discussion 197-8. PubMed ID: 10917362
[TBL] [Abstract][Full Text] [Related]
37. Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model.
Lin YC; Hwang JJ; Wang SJ; Yang BH; Chang CW; Hsiao MC; Chou FI
Anticancer Res; 2012 Jul; 32(7):2657-64. PubMed ID: 22753723
[TBL] [Abstract][Full Text] [Related]
38. Development of an Imaging Technique for Boron Neutron Capture Therapy.
Fukumitsu N; Matsumoto Y
Cells; 2021 Aug; 10(8):. PubMed ID: 34440904
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
40. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy.
Joel DD; Coderre JA; Micca PL; Nawrocky MM
J Neurooncol; 1999 Feb; 41(3):213-21. PubMed ID: 10359141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
